Inhibition of osteosarcoma by European Mistletoe derived val-miR218
2023

Inhibition of Osteosarcoma by Mistletoe-Derived val-miR218

publication Evidence: high

Author Information

Author(s): Xie Wenyan, Delebinski Catharina, Gürgen Dennis, Schröder Maik, Seifert Georg, Melzig Matthias F.

Primary Institution: Institute of Pharmacy, Freie Universität Berlin

Hypothesis

This study aimed to investigate whether mistletoe miRNAs, specifically val-miR218, exert anti-cancer activity against osteosarcoma.

Conclusion

The study demonstrated that val-miR218 significantly inhibits proliferation in various tumor cell lines in vitro and osteosarcoma in vivo.

Supporting Evidence

  • Val-miR218 showed high potential anti-cancer effects against osteosarcoma.
  • 61 genes were identified as direct targets of val-miR218.
  • Val-miR218 significantly inhibited cell growth and arrested osteosarcoma cells in G0/G1 phase.

Takeaway

Mistletoe contains a special molecule called val-miR218 that can help stop cancer cells from growing.

Methodology

The anti-cancer effects of val-miR218 were evaluated using RNA-seq, RT-qPCR, western blot analyses, and in vivo experiments.

Limitations

The study's limitations include the low yield of EVs from mistletoe and the lack of validation of target genes in additional cell lines.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.20517/evcna.2023.15

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication